Drug Alerts and Special Reports

Key reimbursement alerts for office-administered drugs — C-Code, J-Code, NDC, and NCCN alerts plus pricing updates, sent on behalf of pharma manufacturers.

Subscribe To Newsletter

NDC 02/14/2023

New NDC and dose for TURALIO (pexidartinib) - 11/7/22

New NDC and dose for TURALIO® (pexidartinib) (see Prescribing Information and Boxed WARNING) DSI041-TUR-A-02 96 TK ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ TURALIO ® New Dosing Regimen Approved in the U.S. Approved in the U.S. The dosing change is being made due to the known effects food has on the absorption of TURALIO and the potential for drug overexposure that could happen if a patient takes the TURALIO 200…

NDC 02/14/2023

NEW NDC FOR ZILRETTA (triamcinolone acetonide) - 10/17/22

ACTION REQUIRED: NEW NDC FOR ZILRETTA® (triamcinolone acetonide Pacira BioSciences, Inc. acquired Flexion Therapeutics and ZILRETTA. A new NDC has been issued to reflect the updated labeler code for ZILRETTA . Effective October 10, 2022, a new ZILRETTA NDC will be available: 65250-0003-01 HCPCS Code HCPCS Code Descriptor NDC Number Labeler NDC Description J3304 Injection triamcinolone acetonide, preservative free, extended release…

FDA Approved 02/14/2023

Now Approved: RELYVRIO: new ALS treatment option for your members - 10/13/22

Now approved: new ALS treatment option for your members 96 ================================================================================================================================= we need 1k of characters in the head to prevent iOS devices from displaying the "download rest of message"... message... ************************************************************************************************************…

02/14/2023

Effective October 1, 2022: J1932: A unique HCPCS code for Cipla's Lanreotide Depot - 10/3/2022

Effective October 1, 2022: J1932: A unique HCPCS code for Cipla's Lanreotide Depot Effective October 1, 2022: J1932, injection, lanreotide, (Cipla), 1 mg, is available for all sites of care. J1932 is a unique HCPCS code for Cipla's version of Lanreotide Depot and should not be used for billing other lanreotide formulations. HCPCS Code HCPCS Code Descriptor NDC Number How Supplied ASP Per HCPCS Unit (1 mg) HCPCS Units Per Package…

02/14/2023

Effective October 1, 2022: J9274, Injection, tebentafusp-tebn, 1 microgram for KIMMTRAK - 9/22/22

Effective October 1, 2022: J9274, Injection, tebentafusp-tebn, 1 microgram for KIMMTRAK® Effective For Dates of Service Beginning October 1, 2022 KIMMTRAK Permanent J-Code Now Available J9274 Injection, tebentafusp-tebn, 1 microgram KIMMTRAK Coding Details: HCPCS Code HCPCS Code Description NDC NDC Description HCPCS Units Per Package WAC* Per HCPCS Unit J9274 Injection, tebentafusp-tebn, 1 mcg 80446-0401-01 Single Dose Vial Containing…

J-Code 02/14/2023

Announcing A Permanent J-Code for Opdualag - 9/29/22

Announcing A Permanent J-Code for a BMS Oncology Product J9298 Injection, nivolumab and relatlimab-rmbw, 3 mg/1 mg J9298 Injection, nivolumab and relatlimab-rmbw, 3 mg/1 mg EFFECTIVE FOR DATES OF SERVICE ON OR AFTER OCTOBER 1, 2022: The following HCPCS code may be used to identify OPDUALAG™ (nivolumab and relatlimab-rmbw) J9298 Injection, nivolumab and relatlimab-rmbw, 3 mg/1 mg Opdualag is a fixed-dose combination: a co-formulation of…

02/14/2023

ENHERTU: New Indication - 9/28/22

New indication, now approved: ENHERTU® (fam-trastuzumab deruxtecan-nxki) New indication, now approved: ENHERTU® (fam-trastuzumab deruxtecan-nxki) 96 Find out about this new treatment option. Review the PI and Boxed WARNINGS here. ENHERTU ® (fam-trastuzumab deruxtecan-nxki) is NOW APPROVED for the treatment of unresectable or metastatic activating HER2 -mutant 2L non-small cell lung cancer (NSCLC) INDICATION ENHERTU is a HER2-directed…

J-Code 02/14/2023

Coming Soon: Permanent J Code ( J2777) for Vabysmo - 8/30/22

Coming Soon: A Permanent J-code (J2777) for VABYSMO® Coming Soon: A Permanent J-code (J2777) for VABYSMO ® effective for services beginning October 1, 2022 A permanent J-code will go into effect for dates of service beginning October 1, 2022. J2777: Injection, faricimab-svoa, 0.1 mg Please ensure your systems are updated to accept J2777 for VABYSMO for services starting October 1, 2022 VABYSMO NDC Code 50242-0096-01: VABYSMO (6…

Pricing 02/14/2023

Announcing a new WAC for Nexplanon J7307 - 8/25/22

Announcing a new Wholesale Acquisition Cost (WAC) for NEXPLANON® (etonogestrel implant) 68 mg Radiopaque Announcing a New WAC for NEXPLANON Effective August 18, 2022, the new WAC for NEXPLANON WAC is $1,092.48. Please update your claims processing system and any applicable fee schedules for NEXPLANON as soon as possible. The price has been communicated to pricing services. HCPCS Labeler 10 Digit NDC 11 Digit NDC Package Description WAC…

Now Available 02/14/2023

Tivdak J9273 Now Available - 4/6/22

96 J9273 Now Available preheader__here --> J-Code J9273. Effective April 1, 2022. Tivdak (tisotumab vedotin-tftv, for injection 40 mg) has been issued a permanent J-code: J9273 . See Indication, BOXED WARNING, and Important Safety Information below. Indication TIVDAK is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. This indication is approved…

1 … 161718

No alerts match your filters.